Business
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
- Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending D...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n - Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the study in 1Q 2025 at an upcoming major medical meeting\n \n\n - The Phase 1b portion of the trial, in DMD patients, is underway with the intention of enrolling up to 10 adult volunteers with genetically confirmed DMD during 1Q 2025\n \n\n - Phase 2 IND filing on track to be submitted by end of 1Q 2025\n \n\n\n\n\n\n Satellos Bioscience Inc.\n \n\n\n (TSX: MSCL, OTCQB: MSCLF)\n \n (“\n \n Satellos\n \n ” or the “\n \n Company\n \n ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it has completed enrollment of all four multiple-ascending dose (MAD) cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers.\n \n\n “The completion of healthy volunteer enrollment in our Phase 1 trial marks a significant milestone in our mission to develop transformative therapies for patients with degenerative diseases,” said Frank Gleeson, Satellos Co-founder and CEO. “We believe SAT-3247 represents a novel, well-tolerated, and more favorable treatment option as an oral, once-daily therapy designed to restore muscle regeneration and repair in all DMD patients, whether used as a stand-alone drug or an add-on therapy. This progress sets the stage for us to present the first Phase 1 data at an upcoming major medical conference and advances our commitment to deliver meaningful solutions to the DMD community.”\n \n\n\n About Phase 1 DMD Trial\n \n\n\n The Phase 1 clinical trial is comprised of two components. In the first component, 72 healthy volunteers have been enrolled in a blinded, randomized, placebo-controlled, staggered, parallel design study to assess the safety and pharmacokinetic properties of SAT-3247. Participants were randomized across five SAD cohorts, four MAD cohorts, and one food effect dose cohort. The second component, the Phase 1b portion of the trial, is currently ongoing. U...